Differences

Last edited on June 25, 2023

This shows you the differences between two versions of the page.

--- geri:parkinsons [on June 2, 2019]
+++ geri:parkinsons [on November 11, 2019]
@@ Line 150: / Line 150: @@
 ==== Levodopa ====
 <callout type="success">{{fa>arrow-circle-right?color=green}} See main article: **[[meds:dopamine-agonists:carbidopa-levodopa|]]**</callout>
-Administration of dopamine alone is ineffective because dopamine cannot cross the blood–brain barrier. Thus, the main treatment for all patients with Parkinson's is levodopa, a dopamine precursor. When ingested alone, levodopa is rapidly converted to dopamine outside the CNS. Thus carbidopa, a DOPA decarboxylase inhibitor (DDCI), is added to inhibit the conversion of levodopa to dopamine outside the CNS.
+The main treatment for PD is levodopa, a dopamine precursor (since dopamine itself cannot cross the blood–brain barrier). When taken orally, levodopa is rapidly converted to dopamine outside the CNS. Thus carbidopa, a DOPA decarboxylase inhibitor (DDCI), is added to inhibit the conversion of levodopa to dopamine outside the CNS.
 ==== Dopamine Agonists ====
-Dopamine agonists such as [[meds:dopamine-agonists:ropinirole|ropinirole]] and [[meds:dopamine-agonists:pramipexole|pramipexole]] are also used.
+Dopamine agonists include the ergot derivatives: [[meds:dopamine-agonists:bromocriptine|bromocriptine]], cabergoline, dihydroergocryptine, lisuride, and pergolide. There are also the non-ergot derivatives: apomorphine, piribedil, [[meds:dopamine-agonists:pramipexole|pramipexole]], [[meds:dopamine-agonists:ropinirole|ropinirole]], rotigotine.
 ==== Dopamine Agonist Withdrawal Syndrome (DAWS) ====